[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"shock-septic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:shock-septic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,69,107,143,168,202,230,260,283,308,331,359],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100432417","feasibility-of-using-the-cgm-guardian-2-interstitial-fluid-glucose-measurement-system-in-intensive-care-medicine-100432417",false,"NCT04910841","Feasibility of Using the \"CGM GUARDIAN 2\" Interstitial Fluid Glucose Measurement System in Intensive Care Medicine","GALI","Inclusion Criteria:\n\n* Patient in septic shock\n* Arterial hypotension requiring noradrenaline\n* Hyperglycaemia requiring insulin therapy\n\nExclusion Criteria:\n\n* Patients under guardianship, curatorship or deprived of liberty\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":19,"type":20},55,"ESTIMATED","INTERVENTIONAL",[23],"NA","Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice, we use a protocol and management software called \"CPG\" (Personalized Control of Blood Glucose). This involves taking capillary samples from the fingertips. In addition to the pain generated, local haematomas and sensitivity disorders have been described. Night-time sampling also leads to repeated awakenings. The \"CGM GUARDIAN 2\" system has been validated for the measurement of glucose in interstitial fluid in insulin-dependent diabetic patients. An electrode is placed on the patient's abdomen or arm for up to 6 days. This electrode consists of a needle that is inserted subcutaneously only during the placement. The sugar level is read using a sensor placed on the electrode and an insulin pump (which will not deliver therapy (for our study) and which will be used only as an information reader to know the glucose level and trends). Interstitial fluid is automatically drawn from the electrode every minute and averaged every 5 minutes.\n\nThis device has not yet been validated in resuscitation patients.",[26,27,28],"Hyperglycemia","Hypotension","Shock, Septic","RECRUITING","2026-05-21",{"date":32,"type":33},"2026-05-22","ACTUAL",{"date":35,"type":33},"2023-09-11",{"date":37,"type":20},"2026-09",{"name":39,"class":40},"Centre Hospitalier Universitaire de Nice","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":67,"locationsCount":41},"100532832","early-intravenous-hydrocortisone-in-sepsis-100532832","NCT06217939","Early Intravenous Hydrocortisone in Sepsis","Early Intravenous Hydrocortisone in Sepsis: a Randomized Control Trial","EARL-HYDRO","Inclusion Criteria:\n\n* Age of 18 years or older\n* Suspected or definite sepsis Sepsis is defined by SEPSIS-3 definition as Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline with suspected infection.2 Suspected sepsis is defined as patients with suspected infection who meet 2 or more criteria of quick SOFA (altered mentation, respiratory rate ≥ 22\u002Fmin, systolic blood pressure ≤ 100 mmHg).\n* Hypotension (mean arterial pressure \\< 65 mmHg)\n\nExclusion Criteria:\n\n* Randomization and administration of the study drugs are not able to be executed within 3 hours after the onset of hypotension\n* Causes of shock other than sepsis identified\n* Immunocompromised A patient is considered immunocompromised if one of the following criteria is met: history of human immunodeficiency virus infection or acquired immunodeficiency syndrome, hematologic malignancy, receiving chemotherapy, active cancer receiving chemotherapy, current use of immunosuppressive medication)\n* Hyperglycemic crisis (diabetic ketoacidosis, hyperosmolar hyperglycemic state)\n* Pregnancy\n* Post-cardiac arrest\n* Received etomidate before randomization\n* Systemic corticosteroids indicated for other conditions\n* Received systemic corticosteroids within 4 weeks at any dose\n* Cancer patients who are receiving palliative treatment\n* Do-not-resuscitate order",{"count":51,"type":20},230,[23],"The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure.\n\nThe main question it aims to answer is:\n\n• Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines?\n\nParticipants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.",[55,28],"Sepsis Severe",[57,58,59,60],"sepsis","hydrocortisone","shock","early","2026-01-05",{"date":63,"type":33},"2026-01-07",{"date":65,"type":33},"2024-06-25",{"date":37,"type":20},{"name":68,"class":40},"Siriraj Hospital",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100484735","early-severe-illness-translational-biology-informatics-in-humans-100484735","NCT05591924","Early Severe Illness TrAnslational BioLogy InformaticS in Humans","Prospective Observational Study of Biology of Critical Illness","ESTABLISH","Inclusion Criteria:\n\n* Age ≥18 years old\n* ≤48h since ICU admission\n* ICU admission within 72h of presentation to the emergency department (ER)\n* Clinical critical illness suspected on the basis of any one of the following:\n\n  1. Altered mental status (GCS\\\u003C15)\n  2. Cardiovascular collapse (presence of any: Heart rate \\>90, systolic blood pressure \\\u003C90, presence of vasopressors, lactate \\>2.0)\n  3. Respiratory collapse (presence of any: respiratory rate \\>20, PaCO₂ \\\u003C32 mm Hg, supplemental oxygen, invasive or non-invasive ventilation)\n  4. Suspected severe infection (presence of any: temperature \\>38°C or \\\u003C36°C, white blood cell (WBC) count \\>12,000\u002Fmm³ or \\\u003C4,000\u002Fmm³, presence of 1 or more antibiotics at the time of ICU admission)\n\nExclusion Criteria:\n\n* Age \\\u003C18 years old\n* \\>72h since ICU admission\n* Admission to ICU in patients \\>72h after the presentation to the ER\n* No evidence of critical illness (ICU admission due to bed-spacing)",true,{"count":79,"type":20},1000,"24 Months","OBSERVATIONAL","Advanced stages of the response to life-threatening infection, severe trauma, or other physiological insults often lead to exhaustion of the homeostatic mechanisms that sustain normal blood pressure and oxygenation. These syndromic presentations often meet the diagnostic criteria of sepsis and\u002For the acute respiratory distress syndrome (ARDS), the two most common syndromes encountered in the intensive care unit (ICU). Although critical illness syndromes, such as sepsis and ARDS, have separate clinical definitions, they often overlap clinically and share several common injury mechanisms. Moreover, there are no specific therapies for critically ill patients, and as a consequence, approximately 1 in 4 patients admitted to the ICU will not survive.\n\nThe purpose of this observational study is to identify early patient biologic factors that are present at the time of ICU admission that will help diagnose critical illness syndromes earlier, identify who could benefit most from specific therapies, and enable the discovery of new treatments for syndromes such as sepsis and ARDS.",[84,85,86,87,28,88,89,90,91],"Sepsis","ARDS","Critical Illness","Neurocognitive Dysfunction","Ventilator Associated Pneumonia","Immune Suppression","Inflammation","SIRS",[93,84,85,90,94,95,96,97],"Critical Care","Immune responses","Neurocognition","Critical illness","Translational Biology","2025-10-01",{"date":100,"type":33},"2025-10-06",{"date":102,"type":33},"2024-04-26",{"date":104,"type":20},"2034-12-31",{"name":106,"class":40},"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":119,"conditions":120,"keywords":127,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100510835","phase-3-early-initiated-vasopressor-therapy-in-the-emergency-department-100510835","NCT05931601","Early Initiated Vasopressor Therapy in the Emergency Department","Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled Trial","VASOSHOCK","Inclusion Criteria:\n\n* At least 18 years of age\n* Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as:\n\n  1. SBP \\\u003C 100mmHg or MAP \\\u003C 65 mmHg combined with lactate \\> 2.0 mmol\u002FL,\n  2. Physician defined blood pressure for the individual patient combined with a lactate \\> 2.0 mmol\u002FL\n  3. Either SBP \\\u003C 100mmHg or MAP \\\u003C 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician.\n* Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival.\n* Clinical Frailty Score (CFS) of ≤4. If CFS is ≥5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion.\n\nExclusion Criteria:\n\n* Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician.\n* Fertile women (\\\u003C60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding.\n* Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant.\n* Known allergy to noradrenaline.",{"count":116,"type":20},320,[118],"PHASE3","The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid only therapy in patients with hypotensive and shock in the Danish and Swedish Emergency Departments (ED).\n\nThe main questions it aims to answer are:\n\nIf early initiated noradrenaline in non-bleeding hypotensive patients presenting in the ED can\n\n* Improve time to shock control.\n* Reduce the need for ICU admittance.\n* Decrease mortality.\n\nParticipants will be included by the clinical staff and treated urgently with either noradrenaline or usual treatment during their Emergency Department stay.\n\nAfter completion of the treatment in the Emergency Department, patient data will be extracted from the bed-side measurements, electronic health records and national registers.\n\nPatients will be contacted by the research staff 1 year after study inclusion to answer brief questions about their daily physical function and ability to care for themselves.\n\nResearchers will compare with patients receiving fluid therapy only, as this is the usual standard of care in Danish and Swedish Emergency Departments.",[121,28,27,122,123,124,125,126],"Shock","Hypotension and Shock","Hypotension Symptomatic","Hypovolemia","Hypovolemic Shock","Hypovolemic",[128,129,130,131,132],"Peripherally infused noradrenaline","Fluid therapy","Fluid treatment","Non-hemorrhagic shock and hypotension","Emergency Department","2025-06-26",{"date":135,"type":33},"2025-07-01",{"date":137,"type":33},"2023-12-08",{"date":139,"type":20},"2027-01-31",{"name":141,"class":40},"Odense University Hospital",8,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":165,"locationsCount":167},"100434270","mini-fluid-challenge-assessment-a-comparison-among-three-hemodynamic-tools-100434270","NCT04934943","\"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools\"","MINI3","Inclusion criteria\n\n1\\) Acute circulatory failure defined as:\n\n* SAP ≤ 90 mmHg (or a decrease \\> 50 mm Hg in hypertensive patients)\n* or a mean arterial pressure (MAP) ≤ 70 mmHg\n* or the use of vasopressors to maintain SAP \\>90 mmHg,\n* associated with skin mottling; tachycardia ≥100 beats\u002Fmin; urinary flow ≤0.5 mL\u002Fkg for at least 2 hours; blood lactate level ≥4 mmol\u002FL.\n\nExclusion criteria:\n\n* known severe myocardial or valvular dysfunction\n* cardiac arrhythmias\n* severe acute respiratory distress syndrome\n* on-going haemodialysis or continuous hemofiltration\n* moribund patients\n* persistent low quality of the arterial signal affecting hemodynamic monitoring measurements\n* poor echographic windows.",{"count":151,"type":20},45,"The mini fluid challenge (mini\\_FC) is a functional hemodynamic test which has been used in different clinical contexts to assess fluid responsiveness.\n\nThis test is performed by rapidly injecting a small aliquot of fluid (100 ml over 1 minute), which is followed by the infusion of the residual aliquot of fluid.\n\nSince the threshold of the mini\\_FC identified by the literature is rather small (5% of stroke volume (SV) increase after the 100 ml bolus to discriminate between responder and non-responder), it is crucial that the hemodynamic tool assessing this change could be reliable. Moreover, the SV changes with inspiratory\u002Fexpiratory movements and the increase after the mini\\_FC should also consider the physiological fluctuations of the SV.\n\nIn the literature this test has been performed by means of tolls with different least significant change of the SV. The least significant change (LSC) represents the smallest difference between successive measurements of SV that can be considered to be a real change and not attributable to chance.\n\nThe purpose of this study is to assess the agreement among MOSTCARE system (4.5\\& of SV LSC described in the literature) and the echocardiography (about 10% of SV LSC described in the literature) with the PICCO system (about 1% of SV LSC described in the literature - considered the gold standard) in discriminating fluid responsiveness after a mini\\_FC",[84,28,154],"Critically Ill",[156,157],"Fluid challenge","Functional hemodynamic test","NOT_YET_RECRUITING","2025-06-25",{"date":161,"type":33},"2025-06-29",{"date":163,"type":20},"2025-08-01",{"date":163,"type":20},{"name":166,"class":40},"Humanitas Clinical and Research Center",2,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":186,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":41},"100420079","phase-3-management-of-shock-in-children-with-sam-or-severe-underweight-and-diarrhea-100420079","NCT04750070","Management of Shock in Children With SAM or Severe Underweight and Diarrhea","Randomized Controlled Trial of Dopamine, Adrenaline, and Blood Transfusion for Treatment of Fluid Refractory Shock in Children With Severe Acute Malnutrition or Severe Underweight and Cholera or Other Dehydrating Diarrheas","Inclusion Criteria:\n\n1. Children of either sex with acute malnutrition and diarrhea\n2. Age: 1-59 months\n3. Children with cerebral palsy (CP) and\u002For developmental delay, Down Syndrome with or without heart diseases\n4. Fluid refractory shock\n5. Consent from the caregivers\u002Fparents\n\nExclusion Criteria:\n\n1. Having a rare blood group (Rh negative blood groups provided that donor is not available)\n2. A child requiring cardio-pulmonary resuscitation during screening or having gasping respiration","1 Month","59 Months",{"count":178,"type":20},135,[118],"Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths. The coexistence of sepsis and hypovolemic shock in children with severe acute malnutrition (SAM) having diarrhea is common. At Dhaka hospital of icddr,b, the death rate is as high as 40% and 69% in children with severe sepsis and septic shock respectively with co-morbidities such as severe malnutrition.\n\nThe conventional management of SAM children with features of severe sepsis recommended by WHO includes administration of boluses of isotonic saline followed by blood transfusion in unresponsive cases with septic shock; whereas the Surviving Sepsis Campaign (SSC) guideline recommends vasoactive support. To date, no study has evaluated systematically the effects of inotrope(s) and vasopressor or blood transfusion in children with dehydrating diarrhea (for example, in cholera) and SAM having shock and unresponsive to WHO standard fluid therapy.\n\nThis randomized trial will generate evidence whether inotrope and vasopressor or blood transfusion should be selected for severely malnourished children having hypotensive shock and who failed to respond to WHO standard fluid bolus.",[182,28,183,184,185],"Shock Hypovolemic","Blood Transfusion","Adrenaline","Dopamine",[187,188,121,189,190,191,192],"Severe acute malnutrition","Children","Cholera","Dehydrating diarrhea","Severe underweight","Acute malnutrition","2025-04-13",{"date":195,"type":33},"2025-04-16",{"date":197,"type":33},"2021-08-17",{"date":199,"type":20},"2025-11-30",{"name":201,"class":40},"International Centre for Diarrhoeal Disease Research, Bangladesh",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":21,"phases":213,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100335126","phase-2-sevoflurane-sedation-in-patients-with-septic-shock-100335126","NCT03643367","Sevoflurane Sedation in Patients With Septic Shock","Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock","SSiS","Inclusion Criteria:\n\n* Male and female patients, age 18 to 80 years\n* Intensive care Unit (ICU) patients with septic shock (despite fluid resuscitation vasopressors needed to maintain mean arterial pressure ≥65 millimeter of mercury (mmHg), and serum lactate \\>2mmol\u002Fl even with fluid application)\n* Treatment of septic shock on ICU with vasopressors not longer than 12 hours\n* Sedation and mechanical ventilation on ICU\n* Female patients of childbearing potential with negative pregnancy test\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* Previous surgery and\u002For anesthesia (within last 7 days)\n* Application of nitric oxide (NO)\n* Suspected or known intolerance by history to volatile anesthetics (malignant hyperthermia)\n* Immunosuppressive agents\n* Systemic corticosteroids in the phase before hospitalization (\\> 10mg\u002Fd prednisone)\n* Significant concomitant disease (acute cerebral vascular event, acute coronary syndrome, decompensated heart failure, acute pulmonary edema, major cardiac arrhythmia, seizure, burn, chronic kidney disease, end stage liver failure, neuromuscular disease)\n* AIDS\n* Autoimmune disease\n* Organ transplant\n* Subject with active malignancy receiving\n* chemotherapy or radiation treatment within last 60 days\n* Hepatitis B\u002FC virus infection\n* Anti-tumor necrosis factor (TNF) therapy\n* Pregnancy and\u002For Breast feeding\n* Use of cytokine absorber\n* Enrollment in any other clinical trial during the course of this trial, 30 days prior to its beginning or 30 days after its completion","80 Years",{"count":212,"type":20},153,[214],"PHASE2","Recent in vivo studies from others as well as the investigators group demonstrated that volatile anesthetics immunomodulate sepsis and improve outcome. Also, several clinical trials have convincingly shown that application of a volatile anesthetic provides protection in patients undergoing major surgery.\n\nPatients with sepsis are intubated and ventilated and therefore need sedation. So far, most ICU centers use intravenously applied sedatives in these patients. In the proposed study, we will switch sedation from an intravenous to a volatile anesthetic for a short period of time to explore if sepsis markers improve within the following 120 hours upon sevoflurane conditioning.",[28],[84,218,219],"Septic Shock","Sevoflurane Conditioning","2025-03-26",{"date":222,"type":33},"2025-04-01",{"date":224,"type":20},"2026-01",{"date":226,"type":20},"2027-11",{"name":228,"class":40},"University of Zurich",4,{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":237,"targetDuration":239,"studyType":81,"phases":4,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":41},"100576520","types-of-photoplethysmographic-waves-in-adult-patients-with-septic-shock-100576520","NCT06786364","Types of Photoplethysmographic Waves in Adult Patients with Septic Shock","SHOCK PLETH","Inclusion Criteria:\n\n* Adult patients of 18 years of age and above dignossed with septic shock according to the definition stated in Sepsis 3.0\n* Patients with axillary temperature above 36°C\n* Patients and\u002For family that agree to participate in such study and sign the informed consentment\n* Patients that tolerate supine position\n\nExclusion Criteria:\n\n* Patients with Cardiogenic shock, hipovolemic, obstructive and distributive (neurogenic, anafilactic) shock the exception being septic shock\n* Patients with history of any type of cardiac arrhythmia\n* Patients with history of chronic hepatic disease\n* Patients with limited or diffuse systemic sclerosis\n* Patients that have scarring, nail polish or thickened nails that may impede the proper placement and accurate measurement of photoplethysmography with the pulse oximeter\n* Patients with history of heart insufficiency P- atients with septic shock that already have vasopressor aggents",{"count":238,"type":20},116,"1 Day","The objective of this study is to identify the types of Photoplethysmographic waves present in adults with septic shock and determine whether these waves correlate with other variables of tissue hypoperfusion such as capillary refil, serum lactate and mottling score.",[242,243,244],"Shock Septic","Photoplethysmography","Waveform",[246,247,248,243,249],"shock septic","waveform","vasodilation","arterial tone","2025-01-15",{"date":252,"type":33},"2025-01-22",{"date":254,"type":33},"2024-11-01",{"date":256,"type":20},"2025-05-30",{"name":258,"class":259},"Hospital General de México Dr. Eduardo Liceaga","OTHER_GOV",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":21,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":41},"100520879","hemodynamic-phenotype-basedcapillary-refill-time-targeted-resuscitation-in-early-septic-shockandromeda-shock-2-100520879","NCT06062303","Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2","Hemodynamic Phenotype-Based, Capillary Refill Time-Targeted Resuscitation In Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial (A2)","ANDROMEDA-FR","Inclusion Criteria:\n\n* Consecutive adult patients (≥ 18 years)\n* Patients with septic shock according to Sepsis-3 consensus conference. In short, septic shock is defined as suspected or confirmed infection, plus hyperlactatemia and NE requirements due to persistent hypotension, after a fluid load of at least 1000mL in 1h\n* Patient and\u002For relative informed and having signed the information and consent form for participation in the study\n\nExclusion Criteria:\n\n* More than 4 hours since septic shock diagnosis,\n* Anticipated surgery or acute hemodialysis procedure to start during the 6h intervention period\n* Active bleeding,\n* Do not resuscitate status,\n* Child B-C Cirrhosis\n* Underlying disease process with a life expectancy \\\u003C 90 days and\u002For the attending clinician deems aggressive resuscitation unsuitable\n* Refractory shock (high risk of death within 24h)\n* Pregnancy\n* Concomitant severe acute respiratory distress syndrome\n* Patients in whom CRT cannot be accurately assessed\n* Non-affiliation to a social security scheme or to another social protection scheme\n* Patient on AME (state medical aid) (unless exemption from affiliation\n* Patient under legal protection (guardianship, curatorship)\n* Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable\n* Inability, according to the investigator, to understand the study (non-French-speaking patient, cognitive disorders)",{"count":269,"type":20},180,[23],"Over-resuscitation including fluid overload has been associated with increased morbidity (prolonged duration of organ failure) and mortality in septic shock. \"One-size-fits-all\" resuscitation strategies may increase septic shock mortality. However, clinical studies on individualized resuscitation are lacking. Hemodynamic phenotyping may allow to individualize septic shock resuscitation. The ANDROMEDA-SHOCK trial found that a simple clinical and bedside CRT-targeted resuscitation reduces organ dysfunction and 28-day mortality in septic shock. The current study will examine the hypothesis that a CRT-targeted resuscitation based on hemodynamic phenotyping considering within an decision tree usual bedside clinical parameters such as pulse pressure, diastolic blood pressure, fluid responsiveness and cardiac performance can further decrease mortality in septic shock as compared to usual care.",[273,28],"Intensive Care Unit Acquired Weakness","2024-12-03",{"date":276,"type":33},"2024-12-05",{"date":278,"type":33},"2024-02-06",{"date":280,"type":20},"2026-05-30",{"name":282,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":210,"enrollmentInfo":290,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":167},"100515360","pituitary-function-after-recovery-from-septic-shock-among-icu-survivors-100515360","NCT05990491","Pituitary Function After Recovery From Septic Shock Among ICU Survivors","Pituitary Function After Recovery From Septic Shock Among ICU Survivors: A Prospective, Observational Study","Inclusion Criteria:\n\nSeptic shock group:\n\n* Patients 18-80 years of age who meet the definition of septic shock.\n* Vasopressor requirement should be maintained for a period \\> 24 hours and should require ICU stay for a duration of \\> 7 days.\n* Patient should recover from shock and be planned for discharge from the ICU\n\nNon-septic shock group\n\n* Patients 18-80 years of age who planned for discharge from the ICU.with stay for a duration of \\>7 days.\n* Also, they should not have received vasopressor for.a period of \\>24 hours\n\nExclusion Criteria:\n\n* Patients who refuse to provide consent.\n* Age \\\u003C18 years or \\> 80 years of age.\n* Pregnancy or immediate post-partum (\\\u003C 6 months post-delivery).\n* Chronic kidney disease (Stage 5), chronic liver disease (CHILD B or C), severe Chronic obstructive pulmonary disease, Chronic heart failure.\n* Patients with pre-existing hypopituitarism on replacement.\n* Past history of severe post-partum hemorrhage requiring blood transfusion, traumatic brain injury, subarachnoid hemorrhage, pituitary tumor\u002Fsurgery, snake bite envenomation and meningo-encephalitis.\n* Patients who have been on \\> 5 mg prednisolone equivalent for a period of more than 2 weeks at any time in the previous 6 months before admission.",{"count":291,"type":20},90,"Prolonged circulatory shock is associated with marked disturbances in vascular supply to the brain, and endothelial dysfunction which can lead to disseminated intravascular coagulation and microvascular thrombosis. Pituitary dysfunction is documented following post-partum hemorrhage, traumatic brain injury and subarachnoid hemorrhage, which also affect blood flow to the pituitary. However, there are no studies assessing pituitary function in the aftermath of recovery from shock. This will be a prospective observational study of patients admitted in Critical Care Medicine (CCM) ICU who have recovered from prolonged septic shock (Lasting for a period of \\> 24 hours). Blood samples of the participants will be estimated at the time of discharge from the ICU and at 6 months post discharge. Investigators will estimate fasting serum cortisol, TSH, Free T4, Testosterone (in males), Oestrogen (in females), LH, FSH, Prolactin, IGF-1 and plasma ACTH in all participants at both time points (at the time of ICU discharge and at 6-months follow-up). Participants who have borderline serum cortisol values (138-400 nmol\u002Fl) will be subjected to 250ug ACTH stimulation test. Expected outcome of the proposed study is to know proportion of patients having pituitary hormone axis dysfunction. Investigators will also look for pituitary dysfunction persist or revert, or there are new onset dysfunction at 6 month follow up. This would have major implications in the follow up and management of ICU survivors.",[28,294,295],"Pituitary Dysfunction","Hypopituitarism",[297,298,295],"Septic shock","Post intensive care syndrome","2024-10-09",{"date":301,"type":33},"2024-10-15",{"date":303,"type":33},"2023-08-28",{"date":305,"type":20},"2025-08",{"name":307,"class":259},"Sanjay Gandhi Postgraduate Institute of Medical Sciences",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":16,"minAge":314,"maxAge":17,"enrollmentInfo":315,"targetDuration":317,"studyType":81,"phases":4,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":4},"100560747","significance-of-disseminated-intravascular-coagulation-score-in-mortality-for-children-with-shock-100560747","NCT06581172","Significance of Disseminated Intravascular Coagulation Score in Mortality for Children With Shock","Inclusion Criteria:\n\n* All Children with shock and DIC will developed during the period from 1-1-2025 to 31-12-2025\n\nExclusion Criteria:\n\n* Any shock not complicated with DIC","1 Year",{"count":316,"type":20},80,"2 Months","Evaluates whether the DIC score, as defined according to the International Society of Thrombosis and Hemostasis guidelines is associated with mortality in Children with shock and DIC",[28],[321],"DIC score","2024-09-01",{"date":324,"type":33},"2024-09-04",{"date":326,"type":20},"2025-01-01",{"date":328,"type":20},"2026-01-01",{"name":330,"class":40},"Assiut University",{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":337,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":358},"100492179","study-of-progression-of-community-acquired-pneumonia-in-the-hospital-in-patients-with-more-severe-preexisting-diseases-and-immunosuppression-100492179","NCT05688774","Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression","Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis in Patients With More Severe Preexisting Diseases and Immunosuppression to Complement the PROGRESS CAP Cohort","PROGRESSCOMORB","Inclusion Criteria:\n\n1. Hospitalization with community acquired pneumonia (CAP) confirmed by pulmonary infiltrate in chest imaging\n2. Valid informed consent form\n3. Working diagnosis of CAP by enrolling physician\n4. No hospitalization for any reason within 28 days prior to hospitalization for the current episode of CAP\n5. At least 2 out of the five following clinical symptoms:\n\n   * Fever\n   * Cough\n   * Purulent sputum\n   * Shortness of breath or need for respiratory support\n   * Crackling or rales on auscultation, dullness to percussion, or bronchial breathing\n6. At least 1 of the following criteria\n\n   * Known HIV infection or AIDS\n   * Anti-tumor treatment within the past six months\n   * Therapy with corticosteroids ≥ 20mg for ≥ 14 days before enrollment\n   * Non-steroidal immunosuppressive therapy within the past six months\n   * Cytostatic therapy within the past six months\n   * Radiation therapy within the past six months\n   * Bone marrow transplant received\n   * Respiratory support at home via tracheostoma\n   * Cystic fibrosis\n   * Heart failure: New York Heart Association (NYHA) Stadium IV or HFrEF (defined as left ventricular ejection fraction \\\u003C40%).\n   * Decompensated liver disease (Child-Pugh class C)\n   * Diabetes mellitus with HbA1c ≥ 8,5 %\n   * End-stage renal disease requiring dialysis\n   * Pulmonary hypertension (all classes) with mPAP \\> 20 mmHg (right heart catheter)\n\nExclusion Criteria:\n\n1. Participation in this study at an earlier time\n2. More than 48 hours in the hospital before enrollment (for patients directly to intensive care: more than 7 days)\n3. Pregnancy\n4. Breastfeeding\n5. Active tuberculosis\n6. Acute lung injury or acute respiratory distress syndrome for extrapulmonary reasons\n7. Massive aspiration\n8. Sepsis with extrapulmonary focus\n9. Acute pulmonary embolism","99 Years",{"count":341,"type":20},300,"Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.",[344,84,28],"Pneumonia",[346,347,348],"community ascquired pneumonia","CAP","disease progression","2024-03-12",{"date":351,"type":33},"2024-03-13",{"date":353,"type":33},"2022-02-28",{"date":355,"type":20},"2028-02-28",{"name":357,"class":40},"Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps",10,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":16,"minAge":366,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":21,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":41},"100539604","phase-2-intravenous-methylene-blue-for-treating-refractory-neonatal-septic-shock-100539604","NCT06306001","Intravenous Methylene Blue for Treating Refractory Neonatal Septic Shock","Intravenous Methylene Blue for Treating Fluid-refractory, Catecholamine-resistant, Neonatal Septic Shock: a Randomized, Placebo-controlled, Superiority Trial","Screening Criteria: preterm infants (\\\u003C37 weeks, \\\u003C28 days) clinically diagnosed to have septic shock will be screened for inclusion Inclusion criteria: Subjects must fulfill all the following\n\n1. Definite\u002Fprobable sepsis :Clinical syndrome of sepsis for which bedside neonatologist starts intravenous antibiotics AND either a positive culture of otherwise sterile body fluid OR presence of any 2 or more of the following five markers of sepsis: (a) C-reactive protein \\>10 mg\u002FdL; (b) procalcitonin as per age-appropriate cut-off (c) total leukocyte count and absolute neutrophilic count beyond acceptable range (d) chest X-ray adjudged as pneumonia by two independent Neonatologists.\n2. Shock: adapted from the definition given by Davis et al 2017\n\n   1. Either SBP \\\u003C age and gestation appropriate cut-off OR\n   2. Presence of any 2 of the following 6 parameters i. HR \\>205\u002Fmin ii. Central pulses either week OR bounding iii. CRT \\>3 sec OR flash refill (\\\u003C1 sec) iv. skin mottled\u002Fcool OR flushed v. urine output \\\u003C0.5 ml\u002Fkg\u002Fh in the preceding 6 hours vi. DBP \\\u003C age and gestation appropriate cut-off\n3. Fluid and catecholamine-resistant shock: received fluid boluses up to a maximum of 40 ml\u002Fkg followed by catecholamine infusion titrated up to the maximum dose. The catecholamine infusion could be either dopamine (maximum dose 20 µg\u002Fkg\u002Fmin) or epinephrine (maximum dose 0.4 µg\u002Fkg\u002Fmin) or norepinephrine (maximum dose 0.4 µg\u002Fkg\u002Fmin).\n\nExclusion Criteria:\n\nexcluded if ≥1 criterion positive:\n\n1. G6PD deficient or family history of G6PD deficiency\n2. Potentially lethal malformation\n3. Congenital heart disease\n4. Severe acute kidney injury\n5. Family history of allergy to methylene blue or food dyes","0 Days","28 Days",{"count":369,"type":20},130,[214,118],"Preterm infants (born at less than 37 weeks of pregnancy) sometimes develop a serious blood infection leading to low blood pressure, which does not respond to saline or to the standard medicines for increasing blood pressure, such as dopamine and epinephrine. The goal of this research study is to compare the effect of giving an injectable medicine called Methylene blue (MB) versus not giving MB to such preterm infants who are unresponsive to standard treatment. The main questions that this study aims to answer is:\n\n1. Whether MB treatment reduces death to any cause as compared to no MB treatment.\n2. Whether treatment with MB reduces the time to achieve normal blood pressure\n3. Whether treatment with MB reduces the time to stoppage of all blood pressure medications, steroids and normal saline.\n4. Whether treatment with MB improves heart function as measured by echocardiography at 24 and 48 hours.",[373,28],"Neonatal Sepsis",[375,376,297,377],"Methylene blue","Neonate","Clinical trial","2024-03-05",{"date":349,"type":33},{"date":381,"type":20},"2024-03-15",{"date":383,"type":20},"2027-02",{"name":385,"class":40},"Post Graduate Institute of Medical Education and Research, Chandigarh"]